HomeCompareQDROD vs JNJ

QDROD vs JNJ: Dividend Comparison 2026

QDROD yields 6801.56% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 QDROD wins by $1250738535048472.25M in total portfolio value
10 years
QDROD
QDROD
● Live price
6801.56%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1250738535048472.25M
Annual income
$1,215,581,436,672,994,400,000.00
Full QDROD calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — QDROD vs JNJ

📍 QDROD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodQDRODJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, QDROD + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
QDROD pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

QDROD
Annual income on $10K today (after 15% tax)
$578,132.97/yr
After 10yr DRIP, annual income (after tax)
$1,033,244,221,172,045,200,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, QDROD beats the other by $1,033,244,221,172,045,200,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of QDROD + JNJ for your $10,000?

QDROD: 50%JNJ: 50%
100% JNJ50/50100% QDROD
Portfolio after 10yr
$625369267524236.13M
Annual income
$607,790,718,336,497,200,000.00/yr
Blended yield
97.19%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

QDROD
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

QDROD buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricQDRODJNJ
Forward yield6801.56%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$1250738535048472.25M$30.3K
Annual income after 10y$1,215,581,436,672,994,400,000.00$4,689.40
Total dividends collected$1248380634059638.00M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: QDROD vs JNJ ($10,000, DRIP)

YearQDROD PortfolioQDROD Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$690,856$680,156.44$10,592$272.30+$680.3KQDROD
2$44,654,212$43,914,995.45$11,289$357.73+$44.64MQDROD
3$2,700,574,973$2,652,794,966.49$12,123$472.89+$2700.56MQDROD
4$152,828,307,074$149,938,691,853.11$13,141$629.86+$152828.29MQDROD
5$8,093,605,100,498$7,930,078,811,928.28$14,408$846.81+$8093605.09MQDROD
6$401,153,174,213,425$392,493,016,755,892.20$16,021$1,151.60+$401153174.20MQDROD
7$18,610,175,790,400,972$18,180,941,893,992,610.00$18,122$1,588.22+$18610175790.38MQDROD
8$808,178,976,849,279,000$788,266,088,753,550,000.00$20,930$2,228.20+$808178976849.26MQDROD
9$32,857,101,285,493,140,000$31,992,349,780,264,415,000.00$24,792$3,191.91+$32857101285493.12MQDROD
10$1,250,738,535,048,472,200,000$1,215,581,436,672,994,400,000.00$30,274$4,689.40+$1250738535048472.25MQDROD

QDROD vs JNJ: Complete Analysis 2026

QDRODStock

Quadro Resources Ltd. engages in the acquisition, exploration, and development of mineral properties in Canada. It holds 100% interests in the Staghorn gold property, the Costigan Lake property, and the Long Lake property located in west-central Newfoundland. The company also has an option to acquire a 100% interest in the Yellow Fox and Careless Cove properties situated in Newfoundland; and an option to acquire a 51% interest in the Tulks South property located in Newfoundland. In addition, it holds interest in the Conche property situated in the St. Anthony area on the Northern Peninsula, Newfoundland, and Labrador; and an option to acquire a 70% interest in the Seagull Lake property situated near Thunder Bay, Ontario. The company was formerly known as Tri-Gold Resources Corp. and changed its name to Quadro Resources Ltd. in May 2009. Quadro Resources Ltd. is headquartered in Vancouver, Canada.

Full QDROD Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this QDROD vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

QDROD vs SCHDQDROD vs JEPIQDROD vs OQDROD vs KOQDROD vs MAINQDROD vs ABBVQDROD vs MRKQDROD vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.